Cutaneous cryptococcosis in a patient with cutaneous T cell lymphoma receiving therapy with photopheresis and methotrexate.
Photopheresis is being used with increasing frequency as therapy for patients with neoplastic and dermatologic diseases and is being evaluated as therapy for patients with AIDS. We describe a patient with advanced cutaneous T cell lymphoma who developed pulmonary and cutaneous cryptococcosis after receiving therapy with photopheresis and biweekly methotrexate. We consider the potential roles of cutaneous T cell lymphoma, methotrexate, and photopheresis as predisposing factors in the development of serious cryptococcal infections.
Frieden
T R
TR
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Bia
F J
FJ
Heald
P W
PW
Eisen
R N
RN
Patterson
T F
TF
Edelson
R L
RL
D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003453:Cryptococcosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D003881:Dermatomycoses / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D016867:Immunocompromised Host; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D017893:Photopheresis / Q000009:adverse effects*
D000666:Amphotericin B; D008727:Methotrexate